Estrella Immunopharma Inc ESLA Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.41 down $0.03, 7.53% at close Nov 5
Last close · Previous close $0.44
- Market cap
- At the Nov 5 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$0.31Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$0.41down $0.03, 7.53%Thu, Nov 5 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.44Nov 4
- Volume163.05KNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume5.42MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.24 to $3.00; now $0.41
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 5 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
ESLA trailed the S&P 500 in all 6 periods.
| Period | ESLA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ESLA: down 6.8% S&P 500: down 5.4% | ESLA trailed the S&P 500 by 1.4 percentage points Trailed |
| 3M | ESLA: down 45.1% S&P 500: down 4.5% | ESLA trailed the S&P 500 by 40.6 percentage points Trailed |
| YTD | ESLA: down 73.7% S&P 500: up 8.3% | ESLA trailed the S&P 500 by 82.0 percentage points Trailed |
| 1Y | ESLA: down 84.0% S&P 500: up 9.3% | ESLA trailed the S&P 500 by 93.3 percentage points Trailed |
| Long term | ||
| 3Y | ESLA: down 73.2% S&P 500: up 74.8% −35.5% vs +20.5% a year | ESLA trailed the S&P 500 by 148.0 percentage points Trailed |
| 5Y | ESLA: down 95.9% S&P 500: up 67.3% −47.1% vs +10.8% a year | ESLA trailed the S&P 500 by 163.2 percentage points Trailed |
$10,000 invested in ESLA 5 years ago (Nov 5, 2021) would be worth about $413 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,730.
ESLA trailed the S&P 500 in all 6 periods.
| Period | ESLA and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | ESLA: down 6.8% S&P 500: down 5.4% | ESLA trailed the S&P 500 by 1.4 percentage points Trailed |
| 3M | ESLA: down 45.1% S&P 500: down 4.8% | ESLA trailed the S&P 500 by 40.3 percentage points Trailed |
| YTD | ESLA: down 73.7% S&P 500: up 7.5% | ESLA trailed the S&P 500 by 81.2 percentage points Trailed |
| 1Y | ESLA: down 84.0% S&P 500: up 8.2% | ESLA trailed the S&P 500 by 92.2 percentage points Trailed |
| Long term | ||
| 3Y | ESLA: down 73.2% S&P 500: up 68.6% −35.5% vs +19.0% a year | ESLA trailed the S&P 500 by 141.8 percentage points Trailed |
| 5Y | ESLA: down 95.9% S&P 500: up 56.4% −47.1% vs +9.4% a year | ESLA trailed the S&P 500 by 152.3 percentage points Trailed |
$10,000 invested in ESLA 5 years ago (Nov 5, 2021) would be worth about $413 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,645.
All-time high
$21.25
Closing high on . Now 98.1% below that record.
Split-adjusted daily closes since Sep 14, 2021.
Stock splits
ESLA hasn’t split since its price history begins in 2021.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jan 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$12.25M
- Diluted EPS
- −$0.31
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Mar 31, 2024) | $0.00 | −$469.53K | −$0.01 |
| Q4 FY24 (Jun 30, 2024) | $0.00 | −$3.95M | −$0.11 |
| Q1 FY25 (Sep 30, 2024) | $0.00 | −$3.38M | −$0.09 |
| Q2 FY25 (Dec 31, 2024) | $0.00 | −$1.05M | −$0.03 |
| Q3 FY25 (Mar 31, 2025) | $0.00 | −$2.10M | −$0.06 |
| Q4 FY25 (Jun 30, 2025) | $0.00 | −$5.54M | −$0.15 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$2.29M | −$0.05 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$2.31M | −$0.05 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Jun 30, 2021) | $0.00 | −$733.69K | −$733.69 |
| FY22 (Dec 31, 2022) | $0.00 | −$996.10K | −$0.22 |
| FY23 (Jun 30, 2023) | $0.00 | −$11.11M | −$36.35 |
| FY24 (Jun 30, 2024) | $0.00 | −$7.31M | −$0.27 |
| FY25 (Dec 31, 2025) | $0.00 | −$13.06M | −$0.35 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$9.36MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$9.36MLast 12 months
- Capital spending$0.00Last 12 months
Shareholder returns
- $9.32MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $146.67KAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$146.67KAs of Jun 30, 2026
- 0.20As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- −449.2%Last 12 months
Over the last 12 months, Estrella Immunopharma’s net loss was 449.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Estrella Immunopharma Inc
Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS ® technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka’s ARTEMIS ® technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
ESLA news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
ESLA stock FAQ
What is ESLA stock’s price today?
Estrella Immunopharma (ESLA) traded at $0.41 at the close on , down $0.03 (7.53%) from the previous close of $0.44. Over the past 52 weeks it has traded between $0.24 and $3.00.
If you invested $1,000 in ESLA 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in ESLA on would be worth about $41 at the close on , a total return of −95.9%. The same $1,000 would be worth $160 if invested one year ago. Past performance doesn’t predict future returns.
What is ESLA’s P/E ratio?
ESLA’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$0.31).
What are ESLA’s earnings per share?
ESLA’s diluted earnings per share were −$0.31 over the four quarters to , compared with −$0.24 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.05 per share, against −$0.03 a year earlier (how EPS works).
Does ESLA pay a dividend?
Estrella Immunopharma hasn’t paid a dividend in the last twelve months.
What is ESLA’s 52-week high and low?
Over the past 52 weeks ESLA has traded as low as $0.24 and as high as $3.00. At $0.41 at the close on , it is 86.3% below that high and 70.9% above the low.
What is ESLA’s all-time high?
ESLA’s highest closing price was $21.25 on , adjusted for stock splits. At $0.41 at the close on , it is 98.1% below that record.
Has ESLA stock ever split?
No. ESLA hasn’t split since its price history begins in 2021.
How has ESLA stock performed?
Including dividends and measured to the close on , ESLA has returned −73.7% so far this year and −84.0% over the past year, and −95.9% over five years (−47.1% a year). Over the same periods the S&P 500, measured by SPY, returned +8.3%, +9.3% and +67.3%. Past performance doesn’t predict future returns.
What sector and industry is Estrella Immunopharma in?
Estrella Immunopharma is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does ESLA trade on?
Estrella Immunopharma trades on the Nasdaq under the ticker symbol ESLA. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.